A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2023 Primary results published in the Nature Medicine.
16 Oct 2023 According to a Melanoma Research Alliance media release, the US FDA has decided to expand eligibility of Opdivo (nivolumab) to include patients with completely resected Stage IIB and IIC melanoma, based on results form this trial.
13 Oct 2023 According to a Bristol Myers Squibb media release, data from this study will presented at the Society for Melanoma Research Annual Meeting in November.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com